178 related articles for article (PubMed ID: 12225847)
21. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone.
Rosenberg MF; Bikadi Z; Chan J; Liu X; Ni Z; Cai X; Ford RC; Mao Q
Structure; 2010 Mar; 18(4):482-93. PubMed ID: 20399185
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive Evaluation of Multidrug Resistance via Imaging of ABCG2/BCRP Multidrug Transporter in Lung Cancer Xenograft Models.
Li C; Yang Q; Chen Z; Qiu Y; Du Y; Wang R; He Q; Yang J; Zhen H; Kang L
Mol Pharm; 2022 Oct; 19(10):3521-3529. PubMed ID: 35427142
[TBL] [Abstract][Full Text] [Related]
23. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
24. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
25. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
[TBL] [Abstract][Full Text] [Related]
26. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material.
Diestra JE; Scheffer GL; Català I; Maliepaard M; Schellens JH; Scheper RJ; Germà-Lluch JR; Izquierdo MA
J Pathol; 2002 Oct; 198(2):213-9. PubMed ID: 12237881
[TBL] [Abstract][Full Text] [Related]
27. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
28. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Honjo Y; Hrycyna CA; Yan QW; Medina-Pérez WY; Robey RW; van de Laar A; Litman T; Dean M; Bates SE
Cancer Res; 2001 Sep; 61(18):6635-9. PubMed ID: 11559526
[TBL] [Abstract][Full Text] [Related]
29. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
30. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2).
Mohrmann K; van Eijndhoven MA; Schinkel AH; Schellens JH
Cancer Chemother Pharmacol; 2005 Oct; 56(4):344-50. PubMed ID: 15875186
[TBL] [Abstract][Full Text] [Related]
31. ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport.
Nakagawa R; Hara Y; Arakawa H; Nishimura S; Komatani H
Biochem Biophys Res Commun; 2002 Dec; 299(4):669-75. PubMed ID: 12459192
[TBL] [Abstract][Full Text] [Related]
32. Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3).
Paturi DK; Kwatra D; Ananthula HK; Pal D; Mitra AK
Int J Pharm; 2010 Jan; 384(1-2):32-8. PubMed ID: 19782742
[TBL] [Abstract][Full Text] [Related]
33. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells.
Bhatia P; Bernier M; Sanghvi M; Moaddel R; Schwarting R; Ramamoorthy A; Wainer IW
Xenobiotica; 2012 Aug; 42(8):748-55. PubMed ID: 22401348
[TBL] [Abstract][Full Text] [Related]
35. Flow cytometric analysis of breast cancer resistance protein expression and function.
Minderman H; Suvannasankha A; O'Loughlin KL; Scheffer GL; Scheper RJ; Robey RW; Baer MR
Cytometry; 2002 Jun; 48(2):59-65. PubMed ID: 12116365
[TBL] [Abstract][Full Text] [Related]
36. Low levels of ABCG2 expression in adult AML blast samples.
Abbott BL; Colapietro AM; Barnes Y; Marini F; Andreeff M; Sorrentino BP
Blood; 2002 Dec; 100(13):4594-601. PubMed ID: 12393637
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Meyer zu Schwabedissen HE; Kroemer HK
Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.
Suvannasankha A; Minderman H; O'Loughlin KL; Nakanishi T; Greco WR; Ross DD; Baer MR
Leukemia; 2004 Jul; 18(7):1252-7. PubMed ID: 15208643
[TBL] [Abstract][Full Text] [Related]
39. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2.
Kage K; Fujita T; Sugimoto Y
Cancer Sci; 2005 Dec; 96(12):866-72. PubMed ID: 16367905
[TBL] [Abstract][Full Text] [Related]
40. Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.
Ni Z; Bikadi Z; Cai X; Rosenberg MF; Mao Q
Am J Physiol Cell Physiol; 2010 Nov; 299(5):C1100-9. PubMed ID: 20739628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
